Probuphine Panel Review Could Be A Test Of Titan’s Delivery Technology
This article was originally published in The Pink Sheet Daily
FDA will convene an advisory committee review of the buprenorphine implant for opioid dependence – an established use for the drug, but the first in an extended-release delivery system.
You may also be interested in...
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.